logo

For the Inventor, By the Inventor

Hjärup, Sweden

Carl-Magnus A Andersson

This inventor holds 26 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Neuropharmacology. Top assignees: Acadia Pharmaceuticals Inc., Other. Active years: 2003-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carl-Magnus A Andersson. Retrieved from https://idiyas.com/inventor/carl-magnus-a-andersson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 

% Patents Active = 69.2



Average Co-Inventor Count = 4.8

ph-index = 19

Forward Citations = 657(Granted Patents)


Location History:

  • 24564 Hjärup, SE (2007)
  • Hjärup, SE (2009 - 2013)
  • Glostrup, DK (2003 - 2017)
  • Hjarup, SE (2013 - 2020)

Company Filing History:

goldMedal25 out of 94 
 
Acadia Pharmaceuticals Inc.
 patents
silverMedal1 out of 834,513 
Other
 patents

Years Active: 2003-2020

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Selective Serotonin Receptor
Inverse Agonists
Neurodegenerative Diseases
Azacyclic Compounds
N-Substituted Piperidine
Therapeutics
Muscarinic Agonists
Solid Phase Synthesis
26 patents (USPTO):Explore Patents
1. 10525046 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2020-01-07),
2. 10028944 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2018-07-24),
3. 9765053 - Methods of treatment using selective 5-HT2A inverse agonists (2017-09-19),
4. 9566271 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2017-02-14),
5. 9296694 - Azacyclic compounds (2016-03-29),
6. 9211289 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2015-12-15),
7. 8921393 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2014-12-30),
8. 8618130 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2013-12-31),
9. 8377959 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2013-02-19),
10. 8236960 - Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms (2012-08-07),
11. 8227487 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2012-07-24),
12. 8008323 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2011-08-30),
13. 7994193 - Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases (2011-08-09),
14. 7923564 - Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms (2011-04-12),
15. 7732615 - N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms (2010-06-08),

Title: Carl-Magnus A Andersson: A Visionary Swedish Inventor

Introduction: Carl-Magnus A Andersson is a distinguished inventor hailing from Hjärup, Sweden, known for his groundbreaking contributions to various fields.

Latest Patents: Carl-Magnus A Andersson holds several patents in the areas of renewable energy technologies, sustainable materials, and innovative medical devices.

Career Highlights: With a career spanning over two decades, Carl-Magnus A Andersson has worked tirelessly to develop cutting-edge solutions that have revolutionized industries worldwide.

Collaborations: Throughout his career, Carl-Magnus A Andersson has collaborated with leading research institutions, universities, and companies to bring his innovative ideas to life.

Conclusion: Carl-Magnus A Andersson's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…